Cargando…

Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study

The combination of paclitaxel and ramucirumab is the second-line therapy of choice in the treatment of advanced gastric cancer. To date, no biomarkers are available in gastric cancer to predict the outcome of antiangiogenic therapy. The present prospective study included 35 patients undergoing secon...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Alessandro, Rosalba, Refolo, Maria Grazia, Schirizzi, Annalisa, De Leonardis, Giampiero, Donghia, Rossella, Guerra, Vito, Giannelli, Gianluigi, Lolli, Ivan Roberto, Laterza, Maria Maddalena, De Vita, Ferdinando, Messa, Caterina, Lotesoriere, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019360/ https://www.ncbi.nlm.nih.gov/pubmed/35463372 http://dx.doi.org/10.3389/fonc.2022.862116

Ejemplares similares

Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study
por: D’Alessandro, Rosalba, et al.
Publicado: (2023)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)

Inflammatory Mechanisms of HCC Development
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells
por: Refolo, Maria Grazia, et al.
Publicado: (2018)

Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
por: Rakusic, Zoran, et al.
Publicado: (2020)

Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1
por: Lippolis, Catia, et al.
Publicado: (2015)

Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro
por: Carr, Brian I, et al.
Publicado: (2014)

IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2017)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Ramucirumab Plus Paclitaxel: A Possible New Chemotherapy Regimen for Neuroendocrine Carcinoma of the Stomach
por: Motoo, Yoshiharu
Publicado: (2017)

Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel
por: Matsubara, Yuki, et al.
Publicado: (2017)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab
por: Ruzzo, Annamaria, et al.
Publicado: (2020)

Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases
por: Merl, Man Yee, et al.
Publicado: (2020)

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
por: Di Bartolomeo, Maria, et al.
Publicado: (2019)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report
por: Yang, Min Joo, et al.
Publicado: (2021)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Effect of Intake of Extra Virgin Olive Oil on Mortality in a South Italian Cohort with and without NAFLD
por: Bonfiglio, Caterina, et al.
Publicado: (2023)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Kim, Hyung-Don, et al.
Publicado: (2020)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
por: Martin-Liberal, Juan, et al.
Publicado: (2020)

TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
por: Graziano, Francesco, et al.
Publicado: (2020)

Differential Tissue Fatty Acids Profiling between Colorectal Cancer Patients with and without Synchronous Metastasis
por: Notarnicola, Maria, et al.
Publicado: (2018)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
por: Li, Sini, et al.
Publicado: (2020)

Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma
por: Castellana, Marco, et al.
Publicado: (2021)

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
por: Kim, Seung Tae, et al.
Publicado: (2021)

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group
por: Hirata, Kenro, et al.
Publicado: (2020)

Food Network Analysis in Non-Obese Patients with or without Steatosis
por: Donghia, Rossella, et al.
Publicado: (2023)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u2m6v07gogmbcl72qd6n79uppn